Optimistic Buy Rating for Fortress Biotech Driven by Promising CUTX-101 Prospects and FDA Engagement

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fortress Biotech, with a price target of $17.00.

Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Fortress Biotech’s prospects. The FDA’s swift acceptance of the resubmitted NDA for CUTX-101, a treatment for Menkes disease, indicates a strong engagement and highlights the significant unmet medical need it addresses. This rapid turnaround, with a new PDUFA date set for January 14, 2026, suggests a positive outlook for the drug’s approval.
Moreover, the promising clinical data showing a substantial reduction in the risk of death and improved survival rates further supports the potential success of CUTX-101. If approved, Fortress Biotech stands to gain financially from sales milestones, royalties, and a significant share of the proceeds from a Priority Review Voucher. These factors, combined with the current oversold status of the stock, contribute to Pantginis’s optimistic Buy rating.